



Esophageal Oncology group : Treatment map Jan.2025.

UICC 8th	Standard treatment in Japan	Trials ongoing or follow up
Stage I (N0)	Endoscopic resection (ESD/EMR) + CRT Esophagectomy (Thoracoscopic or open esophagectomy) ¹⁾  Concurrent CRT (CF-RT ⁴⁾) 	JCOG2013 (±NeoCF ²)/DCF ³) Esophagectomy: Upper and Middle thoracic Esophageal Squamous Cell Cancer SCLN ⁸) Dissection vs Preservation 2022/8~ Ongoing 
Stage I (N1)	 	JCOG2206 NeoCF ²)/DCF ³) +Esophagectomy: Surgery alone vs Nivolumab vs S-1 2023/7~ Ongoing 
Stage II	Neoadjuvant chemotherapy (Neo DCF ³) + Esophagectomy (Thoracoscopic or open esophagectomy) ¹⁾ 	
Stage III	Adjuvant Nivolumab (Neo CRT + Esophagectomy) 	Concurrent CRT (CF-RT ⁴) (+Salvage esophagectomy or endoscopic resection) 
T4a/M1LYM Resectable	Neoadjuvant chemotherapy + Esophagectomy ¹⁾ 	Concurrent CRT 
T4b/M1LYM Unresectable	Concurrent CRT 	
Stage IVB	1 st line chemotherapy: CF ²) + Pembrolizumab CF ²) +Nivolumab Nivolumab + Ipilimumab 	
Recurrent	2 nd line chemotherapy: Paclitaxel Docetaxel If no previous ICIs ¹²⁾ : Nivolumab Pembrolizumab (CPS ≥10) 	JCOG1510 Concurrent CRT vs. Induction DCF ³) + Concurrent CRT or Esophagectomy 2018/2~ Follow up period 
		JCOG2311 Radiation therapy + Nivolumab + Ipilimumab vs. Nivolumab + Ipilimumab 2014/11~ Ongoing 

1) 2-3 field lymph node dissection 2) CF, CDDP + 5-FU 3) DCF, DOC + CDDP + 5-FU 4) CF-RT, CDDP + 5-FU + radiation therapy

5) IFI, Involved field irradiation 6) ENI, Elective lymph node irradiation 7) FLOT, 5-FU + LV + L-OHP + DOC 8) SCLN, Supraclavicular lymph node

9) EGJ, Esophagogastric junction 10) DOS, DOC + L-OHP + S-1 11) ICI, Immune checkpoint inhibitor